1-5 of 5
Luis Felipe Casado, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

Juan Carlos Hernandez Boluda, MD PhD, Arturo Pereira, MD PhD, Irene Pastor-Galán, MDcal Doctor, Alberto Alvarez-Larrán, MD PhD, Alisa Savchuk, Jose Manuel Puerta, Jose M. Sanchez, Rosa Collado, Álvaro Díaz, Anna Angona, MD PhD, Miguel Sagüés, Valentín García Gutiérrez, PhD, Concepcion Boque, MD PhD, Ignacio Gómez-Centurión, MD, Rolando Vallansot, MD, Luis Palomera, MD PhD, Arantxa Mendizábal, Luis Felipe Casado, MD, Manuel Pérez-Encinas, Raul Perez Lopez, Francisca Ferrer Marin, MD PhD, Fermin Sanchez-Guijo, MD PhD, Carmen Garcia-Hernandez, MD, Natalia de las Heras, Jose Luiz Lopez Lorenzo, MD, Francisco Cervantes, MD PhD, Juan Luis Steegmann, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 47.
https://doi.org/10.1182/blood-2018-99-109976
Published: 2018
Journal Articles

Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC)

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel de Paz, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Ángel Hernández-Rivas, Pilar Cano, Juan Luis Steegmann, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3764.
https://doi.org/10.1182/blood.V120.21.3764.3764
Published: 2012
Journal Articles

Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the “Watch and Wait” Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials

J Valentin Garcia-Gutierrez, MD, PhD, Begoña Maestro, Luis Felipe Casado, MD, PhD, Manuel Perez-Encinas, Isabel Massague, Raquel De Paz, MD, Santiago Osorio, Joaquin Martinez, MD, Guiomar Bautista, MD, Pilar Giraldo, Carmen Burgaleta, Maria Jesús Peñarrubia, Maria José Requena, Carmen Calle, Jose Angel Hernandez-rivas, MD, Pilar Cano, Juan Luis Steegmann, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3768.
https://doi.org/10.1182/blood.V120.21.3768.3768
Published: 2012
Journal Articles

A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials

Luis Felipe Casado, MD, PhD, Begoña Maestro, J. Valentin García-Gutiérrez, Marie Hélène Dumas, Isabel Massague, Pilar Giraldo, MD, PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquín Martínez-López, MD, Guiomar Bautista, MD, Santiago Osorio, Maria José Requena, Luis Palomera, MD, Maria Jesús Peñarrubia, Carmen Calle, Jose Ángel Hernández-Rivas, Carmen Burgaleta, Marcio M Andrade, Sr., MD, Nuria García-Ormena, Juan Luis Steegmann, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3762.
https://doi.org/10.1182/blood.V120.21.3762.3762
Published: 2012
Journal Articles

Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

Luis Felipe Casado, MD, PhD, Isabel Massague, MD, Pilar Giraldo, MD, Manuel Pérez-Encinas, MD, Raquel de Paz, MD, PhD, Joaquin Martínez-López, MD, PhD, Rafael Fores, MD, Santiago Osorio, MD, Maria José Requena, MD, Luis Palomera, MD, María Jesus Peñarrubia, MD, Carmen Burgaleta, MD, PhD, Begoña Maestro, PhD, Juan Luis Steegmann, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1121.
https://doi.org/10.1182/blood.V114.22.1121.1121
Published: 2009